Egetis Q2: Great progress both in Europe and in the US - Redeye

Egetis has launched Emcitate in Germany. The progress made in the US include advancing the US study and securing a Breakthrough Therapy Designation providing improved FDA access, which is confirmed in the upcoming pre-NDA meeting.

Länk till analysen i sin helhet: https://www.redeye.se/research/1123710/egetis-q2-great-progress-both-in-europe-and-in-the-us?utm_source=finwire&utm_medium=RSS